Ocuphire Pharma EPS - Earnings per Share 2010-2024 | IRD
Ocuphire Pharma eps - earnings per share from 2010 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Ocuphire Pharma Annual EPS |
| 2023 |
$-0.46 |
| 2022 |
$0.87 |
| 2021 |
$-3.82 |
| 2020 |
$-5.28 |
| 2019 |
$-2.17 |
| 2018 |
$-21.00 |
| 2017 |
$-44.18 |
| 2016 |
$-20.65 |
| 2015 |
$-37.94 |
| 2014 |
$-52.82 |
| 2013 |
$-33.61 |
| 2012 |
$-28.81 |
| 2011 |
$-57.62 |
| 2010 |
$-86.44 |
| 2009 |
$-24.01 |
| Ocuphire Pharma Quarterly EPS |
| 2024-06-30 |
$-0.30 |
| 2024-03-31 |
$-0.29 |
| 2023-12-31 |
$-0.19 |
| 2023-09-30 |
$0.25 |
| 2023-06-30 |
$-0.24 |
| 2023-03-31 |
$-0.28 |
| 2022-12-31 |
$1.69 |
| 2022-09-30 |
$-0.22 |
| 2022-06-30 |
$-0.25 |
| 2022-03-31 |
$-0.35 |
| 2021-12-31 |
$0.52 |
| 2021-09-30 |
$-0.25 |
| 2021-06-30 |
$-0.52 |
| 2021-03-31 |
$-3.57 |
| 2020-12-31 |
$-3.65 |
| 2020-09-30 |
$-0.33 |
| 2020-06-30 |
$-0.43 |
| 2020-03-31 |
$-0.87 |
| 2019-12-31 |
$4.71 |
| 2019-09-30 |
$-1.96 |
| 2019-06-30 |
$-2.44 |
| 2019-03-31 |
$-2.48 |
| 2018-12-31 |
$-3.96 |
| 2018-09-30 |
$-8.08 |
| 2018-06-30 |
$-5.80 |
| 2018-03-31 |
$-3.16 |
| 2017-12-31 |
$0.00 |
| 2017-09-30 |
$-1.92 |
| 2017-06-30 |
$1.44 |
| 2017-03-31 |
$-43.70 |
| 2016-12-31 |
$-0.96 |
| 2016-09-30 |
$-6.24 |
| 2016-06-30 |
$-3.84 |
| 2016-03-31 |
$-9.60 |
| 2015-12-31 |
$-9.12 |
| 2015-09-30 |
$-9.60 |
| 2015-06-30 |
$-9.60 |
| 2015-03-31 |
$-9.60 |
| 2014-12-31 |
$-4.80 |
| 2014-09-30 |
$-4.80 |
| 2014-06-30 |
$0.00 |
| 2014-03-31 |
$-43.22 |
| 2013-12-31 |
$-4.80 |
| 2013-09-30 |
$-9.60 |
| 2013-06-30 |
$-14.41 |
| 2013-03-31 |
$-4.80 |
| 2012-12-31 |
$0.00 |
| 2012-09-30 |
$-14.41 |
| 2012-06-30 |
$-4.80 |
| 2012-03-31 |
$-9.60 |
| 2011-12-31 |
$4.80 |
| 2011-09-30 |
$-9.60 |
| 2011-06-30 |
$-28.81 |
| 2011-03-31 |
$-24.01 |
| 2010-12-31 |
$-9.60 |
| 2010-09-30 |
$0.00 |
| 2010-06-30 |
$-24.01 |
| 2010-03-31 |
$-52.82 |
| 2009-12-31 |
$14.41 |
| 2009-09-30 |
$-9.60 |
| 2009-06-30 |
$-14.41 |
| 2009-03-31 |
$-14.41 |
| Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
|
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|
